Homepage
Author:
Transpire Bio
Posted Date:
May 11, 2026
Transpire Bio’s ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
Transpire Bio
May 11, 2026
Transpire Bio Announces Opening of New Satellite R&D Facility in Shanghai, China
Transpire Bio
April 28, 2026
Transpire Bio Strengthens its Leadership Team with Appointment of Ewan Livesey as Head of Business Development
Transpire Bio
March 17, 2026
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
Transpire Bio
February 24, 2026
Transpire Bio’s ANDA for Generic Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
Transpire Bio
January 28, 2026
